Haemonetics Corporation today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company’s treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions.
Mr. Burke will join the Company directly from Medtronic, Inc. where he has served as Chief Integration Officer for the integration of Covidien into Medtronic since June 2015, filling the key role of principal operating officer for the integration management office. Previously, he held various Finance positions of increasing responsibility over a 20-year career with Covidien and predecessor companies, including CFO – Europe, Vice President of Corporate Strategy and Portfolio Management, and Vice President of Financial Planning and Analysis.
Christopher Simon, Haemonetics’ CEO, stated: “Bill Burke is a valuable addition to our team at an important point in time. He is a thoughtful, pragmatic leader with a strong background in all elements of strategy and finance, deep knowledge of the medical device industry and a proven ability to build strong teams that deliver peak performance amid complex change.”
Source: Haemonetics
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.